Literature DB >> 25896750

Rituximab causing deep ulcerative suppurative vaginitis/pyoderma gangrenosum.

Priya Selva-Nayagam1, Gayle Fischer, Ian Hamann, Jack Sobel, Craig James.   

Abstract

Pyoderma gangrenosum (PG) is a rare cause of purulent vulvovaginal ulceration. Six recent cases of vulvovaginal pyoderma gangrenosum associated with rituximab are described. All cases were seen in the setting of rituximab used for the treatment of B cell non Hodgkin's lymphoma (NHL). Age range was 50-74; symptoms were present for 2-24 months and severe pain, heavy discharge and large, deep purulent ulcers extending into the vagina were seen. This article reviews previous reports of vulvovaginal pyoderma gangrenosum, discusses important differential diagnoses in this setting, and provides evidence supporting rituximab as the cause of pyoderma gangrenosum in this cohort.

Entities:  

Year:  2015        PMID: 25896750     DOI: 10.1007/s11908-015-0478-5

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  29 in total

1.  Paradoxical reactions to targeted biological treatments: A way to treat and trigger?

Authors:  Alexandra M G Brunasso; Martin Laimer; Cesare Massone
Journal:  Acta Derm Venereol       Date:  2010-03       Impact factor: 4.437

2.  Imatinib induced pyoderma gangrenosum.

Authors:  D J Pinato; R Sharma
Journal:  J Postgrad Med       Date:  2013 Jul-Sep       Impact factor: 1.476

3.  Case of pyoderma gangrenosum showing oral and genital ulcers, misdiagnosed as Behcet's disease at first medical examination.

Authors:  Hiromi Tsuboi
Journal:  J Dermatol       Date:  2008-05       Impact factor: 4.005

4.  Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcgammaRIIIb on neutrophils.

Authors:  Tomoaki Nakagawa; Akito Natsume; Mitsuo Satoh; Rinpei Niwa
Journal:  Leuk Res       Date:  2010-05       Impact factor: 3.156

5.  Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.

Authors:  Carla Casulo; Jocelyn Maragulia; Andrew D Zelenetz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-12-29

6.  Vulvar pyoderma gangrenosum originating from a healed obstetric laceration.

Authors:  Beverly G Reed; Stuart Shippey; Allan Kremp; Eric Belin
Journal:  Obstet Gynecol       Date:  2013-08       Impact factor: 7.661

7.  Reactive nonsexually related acute genital ulcers: review of cases evaluated at Mayo Clinic.

Authors:  Julia S Lehman; Alison J Bruce; David A Wetter; Sara B Ferguson; Roy S Rogers
Journal:  J Am Acad Dermatol       Date:  2010-05-11       Impact factor: 11.527

Review 8.  Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.

Authors:  W P Daniel Su; Mark D P Davis; Roger H Weenig; Frank C Powell; Harold O Perry
Journal:  Int J Dermatol       Date:  2004-11       Impact factor: 2.736

9.  Pyoderma gangrenosum--a review of 24 cases observed over 10 years.

Authors:  Neide Pereira; Maria Manuel Brites; Margarida Gonçalo; Oscar Tellechea; Amérido Figueiredo
Journal:  Int J Dermatol       Date:  2013-05-15       Impact factor: 2.736

10.  Pyoderma gangrenosum complicating pegylated granulocyte colony-stimulating factor in Hodgkin lymphoma.

Authors:  Fiona M Miall; Karen Harman; Ben Kennedy; Martin J S Dyer
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

View more
  5 in total

Review 1.  The continuing evolution of targeted therapy for inflammatory skin disease.

Authors:  C Schlapbach; A A Navarini
Journal:  Semin Immunopathol       Date:  2015-09-30       Impact factor: 9.623

2.  A case of genital pyoderma gangrenosum successfully treated with cyclosporine without relapse of established follicular lymphoma.

Authors:  Lisa Roche; Christian Gulman; Marina O'Kane
Journal:  JAAD Case Rep       Date:  2018-05-07

3.  A case of rituximab-induced pyoderma gangrenosum.

Authors:  Jorge R Georgakopoulos; Gina Rohekar; Fiona E Lovegrove
Journal:  JAAD Case Rep       Date:  2018-10-29

4.  Very Severe and Refractory Noninfectious Cystitis in Patients with Systemic Lupus Erythematosus: Potential Role of Rituximab Therapy.

Authors:  Vanessa Ocampo-Piraquive; Inés Mondragón-Lenis; Juan G De Los Rios; Carlos A Cañas
Journal:  Case Rep Rheumatol       Date:  2021-02-27

5.  Vulvovaginal pyoderma gangrenosum in association with rituximab.

Authors:  Catherine Maloney; Nicholas Blickenstaff; Aman Kugasia; Laura Beth Buford; Mark D Hoffman
Journal:  JAAD Case Rep       Date:  2018-10-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.